Postdischarge pain, fatigue severity and quality of life in COVID-19 survivors

Esma Demirhan; Sevgi Atar; Ömer Kuru

Makale detayları

Postdischarge pain, fatigue severity and quality of life in COVID-19 survivors

Yazarlar:

Esma Demirhan | Sevgi Atar | Ömer Kuru

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Clinical Sciences

Dergi:

The European Research Journal Vol.9 Issue 1, pp.57-65

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001281600

pISSN:

2149-3189

Anahtar kelimeler:

Özet:

 Objectives: Fatigue and pain symptoms were common complaints among post-COVID-19 patients, and these lead to impaired quality of life QoL. We aimed to evaluate severity of pain and fatigue 3 months after disease onset in discharged COVID-19 patients. Methods: Patients were contacted by phone at their third month following disease onset. Demographic data of the patients such as weight, height, body mass index BMI, gender, smoking history, comorbidities, length of hospitalization, duration of stay in the intensive care unit, were recorded. The patients pain and fatigue severities were evaluated by visual analog scale VAS. QoL was questioned with the EuroQol Group Association five-domain, three-level questionnaire EQ-5D-3L. Results: A total of 392 participants enrolled into the study. At admission, 94.6 of the participants had fatigue and 73.7 of them had pain. A high proportion of them still reported fatigue 55.1 and pain 41.3 at third month. The mean value of pain-VAS score was 5.37  3.85, and it was 7.58  2.82 for fatigue-VAS at admission. VAS scores of pain and fatigue at third month were 1.44  2.11 and 2.04  2.40 respectively. While 66.6 of the patients reported moderate-severe pain at disease onset, the rate was 18.1 at the third month. And also almost half had severe pain at admission 48, it was 2.8 at third month. At disease onset 89.6 of the patients reported moderate-severe fatigue severe: 48. Aproximately one third of them had moderate-severe fatigue 27.9 at third month severe: 5.1. The mean value of EQ-VAS score was 26.76  20.26 at admission, and it was 78.84 16.15 at third month. Statistically significant differences were recorded between the disease onset and third month in terms of pain-VAS fatigue-VAS, and EQ-VAS scores  p  0.001. Female gender, ICU admission, long duration of hospitalization, older age, higher BMI scores, multiple comorbidities, fatigue and pain severity were related to the decrease in QoL scores. Conclusions: Hospitalized COVID-19 survivors need ongoing support for pain, fatigue complaints and impaired QoL after discharge. The factors that cause poor QoL should be taken into account during post-COVID-19 follow up.

 Objectives: Fatigue and pain symptoms were common complaints among post-COVID-19 patients, and these lead to impaired quality of life QoL. We aimed to evaluate severity of pain and fatigue 3 months after disease onset in discharged COVID-19 patients. Methods: Patients were contacted by phone at their third month following disease onset. Demographic data of the patients such as weight, height, body mass index BMI, gender, smoking history, comorbidities, length of hospitalization, duration of stay in the intensive care unit, were recorded. The patients pain and fatigue severities were evaluated by visual analog scale VAS. QoL was questioned with the EuroQol Group Association five-domain, three-level questionnaire EQ-5D-3L. Results: A total of 392 participants enrolled into the study. At admission, 94.6 of the participants had fatigue and 73.7 of them had pain. A high proportion of them still reported fatigue 55.1 and pain 41.3 at third month. The mean value of pain-VAS score was 5.37  3.85, and it was 7.58  2.82 for fatigue-VAS at admission. VAS scores of pain and fatigue at third month were 1.44  2.11 and 2.04  2.40 respectively. While 66.6 of the patients reported moderate-severe pain at disease onset, the rate was 18.1 at the third month. And also almost half had severe pain at admission 48, it was 2.8 at third month. At disease onset 89.6 of the patients reported moderate-severe fatigue severe: 48. Aproximately one third of them had moderate-severe fatigue 27.9 at third month severe: 5.1. The mean value of EQ-VAS score was 26.76  20.26 at admission, and it was 78.84 16.15 at third month. Statistically significant differences were recorded between the disease onset and third month in terms of pain-VAS fatigue-VAS, and EQ-VAS scores  p  0.001. Female gender, ICU admission, long duration of hospitalization, older age, higher BMI scores, multiple comorbidities, fatigue and pain severity were related to the decrease in QoL scores. Conclusions: Hospitalized COVID-19 survivors need ongoing support for pain, fatigue complaints and impaired QoL after discharge. The factors that cause poor QoL should be taken into account during post-COVID-19 follow up.

 Objectives: Fatigue and pain symptoms were common complaints among post-COVID-19 patients, and these lead to impaired quality of life QoL. We aimed to evaluate severity of pain and fatigue 3 months after disease onset in discharged COVID-19 patients. Methods: Patients were contacted by phone at their third month following disease onset. Demographic data of the patients such as weight, height, body mass index BMI, gender, smoking history, comorbidities, length of hospitalization, duration of stay in the intensive care unit, were recorded. The patients pain and fatigue severities were evaluated by visual analog scale VAS. QoL was questioned with the EuroQol Group Association five-domain, three-level questionnaire EQ-5D-3L. Results: A total of 392 participants enrolled into the study. At admission, 94.6 of the participants had fatigue and 73.7 of them had pain. A high proportion of them still reported fatigue 55.1 and pain 41.3 at third month. The mean value of pain-VAS score was 5.37  3.85, and it was 7.58  2.82 for fatigue-VAS at admission. VAS scores of pain and fatigue at third month were 1.44  2.11 and 2.04  2.40 respectively. While 66.6 of the patients reported moderate-severe pain at disease onset, the rate was 18.1 at the third month. And also almost half had severe pain at admission 48, it was 2.8 at third month. At disease onset 89.6 of the patients reported moderate-severe fatigue severe: 48. Aproximately one third of them had moderate-severe fatigue 27.9 at third month severe: 5.1. The mean value of EQ-VAS score was 26.76  20.26 at admission, and it was 78.84 16.15 at third month. Statistically significant differences were recorded between the disease onset and third month in terms of pain-VAS fatigue-VAS, and EQ-VAS scores  p  0.001. Female gender, ICU admission, long duration of hospitalization, older age, higher BMI scores, multiple comorbidities, fatigue and pain severity were related to the decrease in QoL scores. Conclusions: Hospitalized COVID-19 survivors need ongoing support for pain, fatigue complaints and impaired QoL after discharge. The factors that cause poor QoL should be taken into account during post-COVID-19 follow up.

 Objectives: Fatigue and pain symptoms were common complaints among post-COVID-19 patients, and these lead to impaired quality of life QoL. We aimed to evaluate severity of pain and fatigue 3 months after disease onset in discharged COVID-19 patients. Methods: Patients were contacted by phone at their third month following disease onset. Demographic data of the patients such as weight, height, body mass index BMI, gender, smoking history, comorbidities, length of hospitalization, duration of stay in the intensive care unit, were recorded. The patients pain and fatigue severities were evaluated by visual analog scale VAS. QoL was questioned with the EuroQol Group Association five-domain, three-level questionnaire EQ-5D-3L. Results: A total of 392 participants enrolled into the study. At admission, 94.6 of the participants had fatigue and 73.7 of them had pain. A high proportion of them still reported fatigue 55.1 and pain 41.3 at third month. The mean value of pain-VAS score was 5.37  3.85, and it was 7.58  2.82 for fatigue-VAS at admission. VAS scores of pain and fatigue at third month were 1.44  2.11 and 2.04  2.40 respectively. While 66.6 of the patients reported moderate-severe pain at disease onset, the rate was 18.1 at the third month. And also almost half had severe pain at admission 48, it was 2.8 at third month. At disease onset 89.6 of the patients reported moderate-severe fatigue severe: 48. Aproximately one third of them had moderate-severe fatigue 27.9 at third month severe: 5.1. The mean value of EQ-VAS score was 26.76  20.26 at admission, and it was 78.84 16.15 at third month. Statistically significant differences were recorded between the disease onset and third month in terms of pain-VAS fatigue-VAS, and EQ-VAS scores  p  0.001. Female gender, ICU admission, long duration of hospitalization, older age, higher BMI scores, multiple comorbidities, fatigue and pain severity were related to the decrease in QoL scores. Conclusions: Hospitalized COVID-19 survivors need ongoing support for pain, fatigue complaints and impaired QoL after discharge. The factors that cause poor QoL should be taken into account during post-COVID-19 follow up.

Makale detayları

Postdischarge pain, fatigue severity and quality of life in COVID-19 survivors

Yazarlar:

Esma Demirhan | Sevgi Atar | Ömer Kuru

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Clinical Sciences

Dergi:

The European Research Journal Vol.9 Issue 1, pp.57-65

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001281600

pISSN:

2149-3189

COVID-19

pain

fatigue

visual analog scale (VAS)

quality of life

EQ-5D-3L

Sayı

Makale detayları

Postdischarge pain, fatigue severity and quality of life in COVID-19 survivors

Yazarlar: Esma Demirhan | Sevgi Atar | Ömer Kuru

Yayıncı: Prusa Medical Publishing

Ana Başlıklar: Clinical Sciences

Dergi: The European Research Journal Vol.9 Issue 1, pp.57-65

Belge Tipi: Makale

Yayın Tarihi: 4/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001281600

pISSN: 2149-3189

COVID-19

pain

fatigue

visual analog scale (VAS)

quality of life

EQ-5D-3L

Sayı

Yazarlar:

Esma Demirhan | Sevgi Atar | Ömer Kuru

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Clinical Sciences

Dergi:

The European Research Journal Vol.9 Issue 1, pp.57-65

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001281600

pISSN:

2149-3189